logo
  • About us
    • Reig Jofre in brief
    • Strategic pillars
    • Company history
    • Locations
  • Products
    • Product categories
    • Pharmaceutical Technologies
      • Antibiotics
      • Injectable products
      • Others
    • Specialty Products
      • Dermatology
      • Osteoarticular
      • Women’s Health
      • Pediatrics
    • Consumer healthcare
    • Healthcare professionals
      and consumers corner
  • R&D
    • R&D
    • Innovation in Collaboration
    • Pipeline
    • Joint projects
  • Services
    • CDMO services
    • CMO services
  • Investors
    • Information note
    • General information
    • Inside information
    • Other relevant information
    • Former relevant facts
    • Financial information
    • Corporate governance
    • General shareholders’ meetings
    • The share
    • Analysts covering the stock
    • Presentations
    • Webcasts
  • News
    • News and repository
    • Reig Jofre in the media (ES)
    • Subscription center
  • Social Responsibility
  • Contact
    • Contact form
    • Work with us
    • Subscription center
  • |
  • ES
  • EN

News

Transparency withour stakeholders

  • Show all
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

14 June 2022

Execution of the scrip dividend

9 June 2022

Reig Jofre informs on the Scrip Dividend Conditions

23 May 2022

Reig Jofre launches Regenail® topical solution for structural nail alterations

28 February 2022

Reig Jofre submits results note on fourth quarter of 2021

15 November 2021

Bioglan and Stada partner to increase capacity to meet rising demand for Parkinson’s treatment

29 October 2021

Reig Jofre submits results note on third quarter of 2021

29 July 2021

Reig Jofre submits results note on second quarter of 2021

22 July 2021

Reig Jofre acquires 100% of REIG JOFRE UK LTD and consolidates its presence in the United Kingdom

21 July 2021

Start of the trading of the new shares within its scrip dividend

6 July 2021

Start of the second temporary share buyback program

6 July 2021

Increase in the bonus-share capital and new shares to be issued

5 July 2021

Completion of the liquidity contract

9 June 2021

Execution of the scrip dividend

4 June 2021

Conditions of the scrip dividend

11 May 2021

Changes in the Board of Directors

29 April 2021

Reig Jofre submits results note on the first quarter of 2021

26 April 2021

Date change for the release of the result note of 1Q 2021

20 April 2021

Reig Jofre opens a subsidiary in Poland

26 March 2021

Reig Jofre convenes its 2021 General Shareholders´ Meeting

26 February 2021

Reig Jofre submits results note on the fourth quarter of 2020

  • 1
  • 2
  • 3
  • …
  • 16

Legal advice – Online store access for employees – RJF connected

© 2020 Laboratorio Reig Jofre

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsRead MoreAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT

Privacy Preference Center

Privacy Preferences